Outcomes
The mean (SD) QALYs over 24 weeks in the spironolactone group were 0.417 (0.058) per participant compared with 0.404 (0.079) per participant in the no active systemic treatment group, giving an incremental difference of 0.013 (95% CI −0.0024 to 0.0289) QALYs using unadjusted available case data (The mean (SD) change from baseline in Acne-QoL symptom subscale score at 24 weeks was 8.15 (6.12) in the spironolactone group compared with 4.46 (6.34) in the no active systemic treatment group. Thus, the incremental difference in score was 3.68 (95% CI 2.26 to 5.11) in favour of the spironolactone group (